EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSECRG00000002825
Gene Symbol: GABRG1
3 Cross references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSECRG00000014086
Gene Symbol: GABRG2
3 Cross references
209 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSECRG00000014931
Gene Symbol: GABRG3
1 Cross references
260 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSECRG00000014879
Gene Symbol: GABRG3
1 Cross references
267 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSECRG00000000368
Gene Symbol: GABBR1
3 Cross references
268 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSECRG00000023027
Gene Symbol: GCGR
3 Cross references
131 Possible Orthologues:

Glucokinase

Ensembl ID : ENSECRG00000000329
Gene Symbol: GCK
3 Cross references
216 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSECRG00000000716
Gene Symbol: GBA1
3 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSECRG00000017431
Gene Symbol: GRIA1
3 Cross references
325 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSECRG00000005176
Gene Symbol: GRIA2
3 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSECRG00000010739
Gene Symbol: GRIA3
3 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSECRG00000002779
Gene Symbol: GRIA4
3 Cross references
254 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).